Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
2 results loaded, newest first. End of these results.
Marvel Biosciences Corp. announced it has signed a Letter of Intent with Novatech for the Phase 1 trial of its drug candidate MB-204, intended for autism spectrum disorder. The company also provided a general corporate update.
Marvel Biosciences signed a letter of intent with Novatech to run a Phase 1 clinical program for autism candidate MB-204. Trial planned in Australia, targeting first-in-human safety, tolerability, and pharmacokinetics; single ascending dose study expected to start in Q4 2026.